top of page
BA7A34C6-C12B-4A28-8C3E-D3C098A28B19.jpeg

 Peer Reviewed Studies

We are currently collating sources of the latest research and peer reviewed publications about HSCT. We will add new articles as soon as we find them.

December

2022

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

Giacomo Boffa, Alessio Signori, Luca Massacesi , Alice Mariottini , Elvira Sbragia, Salvatore Cottone, Maria Pia Amato, Claudio Gasperini, Lucia Moiola, Stefano Meletti, Anna Maria Repice, Vincenzo Brescia Morra , Giuseppe Salemi , Francesco Patti , Massimo Filippi, Giovanna De Luca, Giacomo Lus, Mauro Zaffaroni, Patrizia Sola, Antonella Conte, Riccardo Nistri, Umberto Aguglia, Franco Granella, Simonetta Galgani, Luisa Maria Caniatti, Alessandra Lugaresi, Silvia Romano, Pietro Iaffaldano, Eleonora Cocco, Riccardo Saccardi, Emanuele Angelucci, Maria Trojano, Giovanni Luigi Mancardi, Maria Pia Sormani, Matilde Inglese; Italian BMT-MS Study Group, Italian MS Register

PubMed

July

2022

Stem Cell Therapy in Neuroimmunological Diseases and Its
Potential Neuroimmunological Complications

Franz Felix Konen, Philipp Schwenkenbecher
, Konstantin Fritz Jendretzky
, Stefan Gingele
,Lea Grote-Levi, Nora Möhn
, Kurt-Wolfram Sühs 1
, Britta Eiz-Vesper 2
, Britta Maecker-Kolhoff, Corinna Trebst, Thomas Skripuletz,Martin W. Hümmert

Cells

July

2022

High-dose immunosuppressive therapy with autologous hematopoietic stem cells transplantation for multiple sclerosis: Current view

Alexey Yu. Polushin, Evgeniya I. Lopatina, Yury R. Zalyalov, Alexander A. Tsynchenko, Natalia A. Totolyan, Alexander D. Kulagin
Pavlov University, St. Petersburg, Russia

Cellular Therapy and Transplantation (CTT)

February

2022

ACTRIMS2022 – Immune System ‘Reset’ by Stem Cell Transplant (fully myeloablative)

Maria Wexler

Multiple Sclerosis News Today

February

2022

Blood Stem Cell Transplant May Help Immune System Longer

Lindsey Shapiro PhD

Multiple Sclerosis News Today

February

2022

Autologous hematopoietic stem cell transplantation vs low-dose immunosuppression in secondary-progressive multiple sclerosis

Alice Mariottini, Giovanni Bulgarini, Benedetta Forci, Chiara Innocenti, Fabrizia Mealli, Alessandra Mattei, Chiara Ceccarelli, Anna Maria Repice, Alessandro Barilaro, Claudia Mechi, Riccardo Saccardi, Luca Massacesi

PubMed

February

2022

HSCT versus cyclophosphamide for progression is no better

The Mouse Doctor

The MS Blog

October

2021

Relapse-independent multiple sclerosis progression under natalizumab

Jonas Graf, Verena I Leussink, Giulia Soncin, Klaudia Lepka, Ingrid Meinl, Tania Kümpfel, Sven G Meuth, Hans-Peter Hartung, Joachim Havla, Orhan Aktas, Philipp Albrecht

PubMed

September

2021

Real‑world application of autologous hematopoietic stem cell
transplantation in 507 patients with multiple sclerosis

Richard K. Burt, Xiaoqiang Han, Kathleen Quigley, Irene B Helenowski, Roumen Balabanov

Journal of Neurology

September

2021

Splitting the Total Dose of Cyclophosphamide in Two Blocks Apart during the Conditioning of Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Results in Diminished Cardiotoxicity: Experience in 1,000 Patients

Juan Carlos Olivares-Gazca, Francisco Guerrero-Pesqueira, Iván Murrieta-Alvarez, Yahveth Cantero-Fortiz, Andrés A León-Peña, José M Priesca-Marín, David Gomez-Almaguer, Andrés Gomez-De-Leon, Guillermo J Ruiz-Delgado, Guillermo J Ruiz-Argüelles

PubMed

September

2021

Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort

José Carlos Jaime-Pérez , Mariana González-Treviño , Jesús D Meléndez-Flores , Eugenia M Ramos-Dávila , Olga G Cantú-Rodriguez , César H Gutiérrez-Aguirre, Dionicio A Galarza-Delgado, David Gómez-Almaguer

PubMed

August

2021

Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series

London Group on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Pubmed

July

2021

Autologous hematopoietic stem cell
transplantation with low-intensity
conditioning regimens in relapsing remitting
multiple sclerosis: clinical outcomes and
quality of life

Vladimir Y. Melnichenko, Denis A. Fedorenko,
Tatiana. P Nikitina,
Natalia. M. Porfirieva
Ilya S. Nikolaev,
Tatiana I. Ionova

Cellular Therapy and Transplantation (CTT)

July

2021

New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis

Richard K Burt, Paolo A Muraro, Dominique Farge, Maria Carolina Oliveira, John A Snowden, Riccardo Saccardi, Xiaoqiang Han, Kathleen Quigley, Valquiria Bueno, Daniela Frasca, Denis Fedorenko, Joachim Burman

PubMed

March

2021

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis

Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, Fredrik Piehl

Neurology.org

March

2021

Stem Cell Therapy as a Treatment for Autoimmune Disease-Updates in Lupus, Scleroderma, and Multiple Sclerosis

Sendhilnathan Ramalingam, Ankoor Shah

PubMed

February

2021

Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

Italian BMT-MS Study Group

Neurology.org

February

2021

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

Jakob R. Passweg, Helen Baldomero, Christian Chabannon, Grzegorz W. Basak, Rafael de la Cámara, Selim Corbacioglu, Harry Dolstra, Rafael Duarte, Bertram Glass, Raffaella Greco, Arjan C. Lankester, Mohamad Mohty, Régis Peffault de Latour, John A. Snowden, Ibrahim Yakoub-Agha & Nicolaus Kröger for the European Society for Blood and Marrow Transplantation (EBMT)

Nature

February

2021

Stem Cell Blood Transfusion Slows the Progression of Relapsing-Remitting Multiple Sclerosis

Christine Lehmann

NeurologyToday

February

2021

Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT)

P Tappenden, Y Wang, B Sharrack, J Burman, M Kazmi, R Saccardi, I Bermejo, R Harvey, M Badoglio, D Farge, J A Snowden

PubMed

February

2021

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE)

PubMed

February

2021

General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE)

PubMed

August

2020

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

Sponsor:
Northwestern University
Collaborators:
Uppsala University
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sao Paulo
Information provided by (Responsible Party):
Richard Burt, MD, Northwestern University

ClinicalTrials.gov

October

2019

The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party

John A Snowden, Manuela Badoglio, Tobias Alexander

PubMed

September

2019

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

Basil Sharrack, Riccardo Saccardi, Tobias Alexander, Manuela Badoglio, Joachim Burman, Dominique Farge, Raffaella Greco, Helen Jessop, Majid Kazmi, Kirill Kirgizov, Myriam Labopin, Gianluigi Mancardi, Roland Martin, John Moore, Paolo A. Muraro, Montserrat Rovira, Maria Pia Sormani & John A. Snowden for the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE)

Nature

June

2019

A general practitioner's guide to hematopoietic stem-cell transplantation

A Bazinet, G Popradi

PubMed

February

2019

Position statement providing general information for patients and carers considering HSCT for severe autoimmune diseases

AUTOIMMUNE DISEASES WORKING PARTY (ADWP) JACIE COMMITTEE PATIENT ADVOCACY COMMITTEE NURSING SCIENTIFIC COMMITTEE

EBMT.org

January

2019

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial

Richard K Burt, Roumen Balabanov, Joachim Burman, Basil Sharrack, John A Snowden, Maria Carolina Oliveira, Jan Fagius, John Rose, Flavia Nelson, Amilton Antunes Barreira, Kristina Carlson, Xiaoqiang Han, Daniela Moraes, Amy Morgan, Kathleen Quigley, Kimberly Yaung, Regan Buckley, Carri Alldredge, Allison Clendenan, Michelle A Calvario, Jacquelyn Henry, Borko Jovanovic, Irene B Helenowski

PubMed

July

2017

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

Bonaventura Casanova, Isidro Jarque, Francisco Gascón, Juan Carlos Hernández-Boluda, Francisco Pérez-Miralles, Javier de la Rubia, Carmen Alcalá, Jaime Sanz, Javier Mallada, Angeles Cervelló, Arantxa Navarré, María Carcelén-Gadea, Isabel Boscá, Sara Gil-Perotin, Carlos Solano, Miguel Angel Sanz, Francisco Coret

PubMed

February

2017

NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs

Richard K Burt, Paolo A Muraro, Dominique Farge, Maria Carolina Oliveira, John A Snowden, Riccardo Saccardi, Xiaoqiang Han, Kathleen Quigley, Valquiria Bueno, Daniela Frasca, Denis Fedorenko, Joachim Burman

PubMed

July

2015

Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives

Jury L Shevchenko, Alexey N Kuznetsov, Tatyana I Ionova, Vladimir Y Melnichenko, Denis A Fedorenko, Kira A Kurbatova, Gary I Gorodokin, Andrei A Novik

PubMed

February

2010

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases

Dominique Farge, Myriam Labopin, Alan Tyndall, Athanasios Fassas, Gian Luigi Mancardi, Jaap Van Laar, Jian Ouyang, Tomas Kozak, John Moore, Ina Kötter, Virginie Chesnel, Alberto Marmont, Alois Gratwohl, Riccardo Saccardi

PubMed

bottom of page